Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291432 · ClinicalTrials.gov registry record · Phase 1
Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
A Phase 1 study, sponsored by Cook MyoSite.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02291432: Completed Phase 1 study, sponsored by Cook MyoSite.
NCT02291432 is a Phase 1 study that has completed, run by Cook MyoSite. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02291432, a Phase 1 study, has completed, sponsored by Cook MyoSite.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.
Primary Outcome
Safety of AMDC-USR following treatment of SUI in male patients who have undergone prior prostate surgery was determined by the frequency and severity of adverse events related to study procedures and study product through 24 months following treatment of SUI in male patients who have undergone prior prostate surgery.
Interventions
- BIOLOGICAL autologous muscle-derived cells (AMDC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-02-19 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 1 |
What the finished NCT02291432 record still lists
NCT02291432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which autologous muscle-derived cells (AMDC) is the first listed.
NCT02291432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02291432 about?
NCT02291432 is a clinical study titled "Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery". To study the safety and potential efficacy of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of male stress urinary incontinence (SUI) for patients that have undergone prior prostate surgery.
What is the current status of trial NCT02291432?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-02-19. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02291432?
The interventions under investigation include: autologous muscle-derived cells (AMDC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02291432?
This trial is sponsored by Cook MyoSite, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02291432's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI